Every condition that qualifies for the Georgia Low-THC Oil Patient Registry, grouped by the 2017 NASEM consensus report evidence tiers. Cross-linked to clinical condition pages where available. Compiled by the Miracle Leaf® physician network.
Statutory authority: Georgia Low-THC Oil Patient Registry. Patient minimum age: 18. Out-of-state reciprocity: Not honored.
See the full step-by-step process on the Georgia medical marijuana card guide.
Conclusive or substantial evidence
Chronic Pain
Pain persisting beyond expected healing time, lasting months or longer. Cannabis and cannabinoids have substantial evidence for treating chronic pain in adults.
Multiple Sclerosis Spasticity
Patient-reported muscle spasticity in adults with multiple sclerosis. The 2017 NASEM consensus report found substantial evidence that oral cannabinoids improve patient-reported MS spasticity symptoms in adults.
Seizure Disorders
Neurological conditions involving abnormal electrical activity in the brain that produces seizures. Cannabidiol has strong evidence for reducing seizure frequency in specific syndromes (Dravet, Lennox-Gastaut, and tuberous sclerosis complex) and is FDA-approved as Epidiolex for those indications.
Moderate evidence
Cancer
Group of diseases involving uncontrolled cell growth. Cannabis and cannabinoids have substantial evidence for treating chemotherapy-induced nausea and vomiting (CINV) and moderate evidence for improving sleep disturbance among cancer patients; antitumor effects remain investigational.
HIV/AIDS
Viral infection that progressively weakens the immune system. Cannabis and cannabinoids have moderate evidence for improving appetite and weight gain in HIV/AIDS-associated wasting, and limited evidence for symptomatic relief in HIV-associated peripheral neuropathy.
Terminal Illness
Illness expected to result in death within a defined prognosis window (often six to twelve months). Cannabis has moderate evidence for managing common end-of-life symptoms (pain, nausea, anorexia, anxiety, sleep disturbance) and is a qualifying condition under most state medical cannabis programs without further diagnosis-specific gating.
Limited evidence
Post-Traumatic Stress Disorder
A trauma- and stressor-related disorder that follows exposure to a traumatic event. The 2017 NASEM consensus report found limited evidence that nabilone is effective for improving sleep outcomes in PTSD; broader symptom relief evidence remains limited.
Amyotrophic Lateral Sclerosis (ALS)
Progressive neurodegenerative disease affecting motor neurons. Cannabis has limited evidence for managing spasticity, sleep, pain, and appetite loss in ALS patients; no evidence to date demonstrates disease-modifying effects.
Crohn's Disease
Chronic inflammatory bowel disease affecting any portion of the gastrointestinal tract. Cannabis has limited evidence for symptomatic improvement (pain, sleep, appetite) in Crohn's patients but no evidence for inducing or maintaining clinical remission.
Parkinson's Disease
Progressive neurodegenerative disorder primarily affecting movement. Cannabis has limited evidence for symptomatic relief of tremor, sleep disturbance, and pain in Parkinson's patients; no evidence of disease-modifying or neuroprotective effect to date.
Sickle Cell Disease
Inherited red blood cell disorder causing chronic anemia, vaso-occlusive pain crises, and end-organ damage. Cannabis has limited evidence for managing chronic and acute sickle-cell pain; clinical trials are ongoing.
Tourette Syndrome
Neurodevelopmental disorder characterized by multiple motor tics and one or more vocal tics. Cannabis has limited evidence for reducing tic severity in adults with treatment-resistant Tourette syndrome.
Alzheimer's Disease
Progressive neurodegenerative disease and the most common cause of dementia. Cannabis has limited evidence for managing behavioral and psychological symptoms of dementia (agitation, sleep disturbance, appetite loss); no evidence demonstrates disease-modifying effects.
Insufficient evidence
Autism Spectrum Disorder
Neurodevelopmental condition characterized by differences in social communication and restricted/repetitive behaviors. Cannabis has insufficient high-quality evidence for treating core autism symptoms; limited evidence exists for managing severe behavioral symptoms in specific subgroups.
Diagnosis documentation
Georgia physicians evaluate qualifying patients against the statutory criteria during the visit. Bring documentation of your condition from your treating clinician: a recent office note, hospital discharge summary, specialist letter, or radiology or pathology report works in most cases. Miracle Leaf® staff can confirm whether your records meet the program requirement before you schedule the evaluation.
Frequently asked questions
Is recreational marijuana legal in Georgia?
No. Possession of less than 1 oz is a misdemeanor under O.C.G.A. §16-13-2 with up to 1 year in jail and a $1,000 fine. Possession of more than 1 oz is a felony with 1 to 10 years and a $5,000 fine. Atlanta, Savannah, and Athens-Clarke County operate municipal civil-fine ordinances, but those do not override state law.
Who qualifies for the Georgia Low-THC Oil Patient Registry?
Per O.C.G.A. §16-12-201, qualifying conditions include cancer (end-stage or treatment-induced symptoms), ALS, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's, sickle-cell, Tourette syndrome, autism, epidermolysis bullosa, Alzheimer's, AIDS, peripheral neuropathy, hospice or terminal diagnosis, intractable pain, and PTSD. Most conditions require severe or end-stage status.
What are Georgia medical possession limits?
Registered patients may possess up to 20 fluid ounces of low-THC oil under their state Low-THC Oil Patient Registry ID card. THC content is capped at 5% by weight. Approved product forms are oils, tinctures, transdermal patches, lotions, and capsules. Smokable flower and edibles are prohibited.
Can Georgia patients grow cannabis at home?
No. Home cultivation is prohibited under Georgia law. All low-THC oil must be purchased from a state-licensed dispensary. The first two dispensaries (Trulieve Georgia in Marietta and Botanical Sciences in Macon) opened on April 28, 2023.
Sources and citations
- O.C.G.A. § 16-12-200 et seq.: Low-THC Oil / Hope Act
- Georgia Access to Medical Cannabis Commission
- NORML: Georgia Laws & Penalties
Last reviewed: 2026-05-17. Evidence tiers reflect the 2017 NASEM consensus report on cannabis and cannabinoids. Not medical advice — consult a licensed clinician.